ATE430570T1 - Synergistische kombinationstherapie zur krebsbehandlung - Google Patents

Synergistische kombinationstherapie zur krebsbehandlung

Info

Publication number
ATE430570T1
ATE430570T1 AT01920653T AT01920653T ATE430570T1 AT E430570 T1 ATE430570 T1 AT E430570T1 AT 01920653 T AT01920653 T AT 01920653T AT 01920653 T AT01920653 T AT 01920653T AT E430570 T1 ATE430570 T1 AT E430570T1
Authority
AT
Austria
Prior art keywords
combination therapy
cancer treatment
synergistic combination
synergistic
cancer
Prior art date
Application number
AT01920653T
Other languages
English (en)
Inventor
Francis Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE430570T1 publication Critical patent/ATE430570T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01920653T 2000-03-27 2001-03-22 Synergistische kombinationstherapie zur krebsbehandlung ATE430570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19227800P 2000-03-27 2000-03-27
PCT/US2001/009193 WO2001072721A2 (en) 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
ATE430570T1 true ATE430570T1 (de) 2009-05-15

Family

ID=22709017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920653T ATE430570T1 (de) 2000-03-27 2001-03-22 Synergistische kombinationstherapie zur krebsbehandlung

Country Status (24)

Country Link
US (1) US6537988B2 (de)
EP (1) EP1272193B1 (de)
JP (1) JP5110756B2 (de)
KR (1) KR20020084254A (de)
CN (1) CN100384424C (de)
AR (1) AR028296A1 (de)
AT (1) ATE430570T1 (de)
AU (2) AU2001247683B2 (de)
BR (1) BR0109517A (de)
CA (1) CA2404712A1 (de)
CZ (1) CZ20023220A3 (de)
DE (1) DE60138611D1 (de)
ES (1) ES2325055T3 (de)
HU (1) HUP0301690A3 (de)
IL (1) IL151373A0 (de)
MX (1) MXPA02009463A (de)
MY (1) MY127082A (de)
NO (1) NO20024610L (de)
PE (1) PE20011291A1 (de)
RU (1) RU2264217C2 (de)
TW (1) TWI310684B (de)
UY (1) UY26635A1 (de)
WO (1) WO2001072721A2 (de)
ZA (1) ZA200207766B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312695T3 (es) * 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
CA2424345A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003041658A2 (en) * 2001-11-13 2003-05-22 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
GEP20063806B (en) * 2001-12-20 2006-04-25 Bristol Myers Squibb Co Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
BR0310026A (pt) * 2002-05-17 2005-02-15 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
EP1506286B1 (de) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralisierung eines menschlichen anti-igfr-antikörpers
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
CN101816792A (zh) * 2002-06-10 2010-09-01 诺瓦提斯公司 包含埃坡霉素的组合及其药学用途
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
EP2186811A1 (de) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP2006526662A (ja) * 2003-06-05 2006-11-24 アシュカル，チャールズ 過増殖性細胞疾患を治療する方法
EP1493445A1 (de) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1735350B1 (de) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
KR20080019733A (ko) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
GB0419071D0 (en) 2004-08-26 2004-09-29 Mgx Internat Ltd Display device
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
PT1828249E (pt) * 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
CA2594482C (en) * 2005-01-19 2013-10-01 Zeria Pharmaceutical Co., Ltd. Antitumor agent
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
RU2276613C1 (ru) * 2005-03-17 2006-05-20 Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) Способ лечения злокачественных опухолей головки поджелудочной железы
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US8101728B2 (en) * 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
EP1942937A1 (de) 2005-11-04 2008-07-16 Wyeth Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US8044033B2 (en) * 2006-03-02 2011-10-25 The Board Of Regents Of The University Of Texas System Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer
EP2029156A4 (de) * 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
RU2325914C2 (ru) * 2006-06-15 2008-06-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ лечения операбельного рака молочной железы
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080085881A1 (en) * 2006-10-06 2008-04-10 Aimery De Gramont Stop-and-go oxaliplatin treatment regimens
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
EP2131849B1 (de) * 2007-03-02 2011-10-26 The University Of Wollongong Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
WO2009035718A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
WO2009033204A1 (en) * 2007-09-12 2009-03-19 University Of Wollongong Multi-component compositions and methods for delivery of anti-cancer agents
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2082745T3 (da) 2007-12-28 2013-03-25 Deutsches Krebsforsch Kræftterapi med en parvovirus kombineret med kemoterapi
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
RU2365370C1 (ru) * 2008-04-29 2009-08-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН Способ лечения рака легкого
BRPI0914790A2 (pt) * 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2370103B1 (de) * 2008-11-28 2016-03-23 Novartis AG Arzneimittelkombinationen, enthaltend einen von isoxazol abgeleiteten hsp90-hemmer und den her2-hemmer trastuzumab
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
PL2500036T3 (pl) * 2011-03-18 2014-10-31 Metheresis Translational Res Sa Inhibitory met do zwiększania skuteczności radioterapii
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103374000B (zh) * 2012-04-13 2015-11-11 中国科学院广州生物医药与健康研究院 嘧啶并二氮杂卓类化合物及其药用组合物和应用
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
US10233226B2 (en) 2017-06-21 2019-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
US12428490B2 (en) 2018-06-13 2025-09-30 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
US11068254B1 (en) 2020-06-10 2021-07-20 Cigna Intellectual Property, Inc. Systems and methods for generating and managing domain-based technology architecture
CA3222225A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19706584C2 (de) * 1997-02-21 2002-09-26 Aeg Energietechnik Gmbh Hochtemperaturbrennstoffzellen mit Erwärmung des Reaktionsgases
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002573A1 (en) * 1997-07-08 1999-01-21 Union Carbide Chemicals & Plastics Technology Cor Poration Method for reducing sheeting during olefin polymerization
DK1041985T3 (da) 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
KR100708360B1 (ko) * 1999-01-21 2007-04-17 브리스톨-마이어스스퀴브컴파니 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법

Also Published As

Publication number Publication date
IL151373A0 (en) 2003-04-10
RU2264217C2 (ru) 2005-11-20
CZ20023220A3 (cs) 2003-11-12
MY127082A (en) 2006-11-30
EP1272193A2 (de) 2003-01-08
BR0109517A (pt) 2006-08-29
HUP0301690A3 (en) 2005-05-30
CA2404712A1 (en) 2001-10-04
WO2001072721A2 (en) 2001-10-04
RU2002129000A (ru) 2004-03-27
AU4768301A (en) 2001-10-08
JP5110756B2 (ja) 2012-12-26
CN1419452A (zh) 2003-05-21
ES2325055T3 (es) 2009-08-25
US6537988B2 (en) 2003-03-25
EP1272193B1 (de) 2009-05-06
HUP0301690A2 (hu) 2003-08-28
AR028296A1 (es) 2003-04-30
UY26635A1 (es) 2001-10-25
WO2001072721A3 (en) 2002-06-13
ZA200207766B (en) 2003-01-20
PE20011291A1 (es) 2002-01-13
KR20020084254A (ko) 2002-11-04
JP2003528864A (ja) 2003-09-30
US20020002162A1 (en) 2002-01-03
NO20024610L (no) 2002-11-25
CN100384424C (zh) 2008-04-30
TWI310684B (en) 2009-06-11
AU2001247683B2 (en) 2006-01-12
MXPA02009463A (es) 2003-04-10
DE60138611D1 (de) 2009-06-18
NO20024610D0 (no) 2002-09-26

Similar Documents

Publication Publication Date Title
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
ATE279190T1 (de) Synergistische zusammensetzungen zur krebsbehandlung
KR100695846B9 (ko) 암 치료
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
GB0316912D0 (en) Therapeutic treatment
AU2002342613A8 (en) Treatment for wounds
IL169633A0 (en) Combination therapy for treating protein deficiencies
HUP0500424A2 (en) Combination therapy for the treatment of cancer
GB0320806D0 (en) Therapeutic treatment
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
DE60135248D1 (de) Immuntherapeutische kombinationen zur tumorbehandlung
GB0001710D0 (en) Therapeutic treatment
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
AU2096002A (en) Therapeutic treatment
GB0026015D0 (en) Cancer treatment
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
DE60017250D1 (de) Synergistische zusammensetzung zur krebsbehandlung
EP1684795A4 (de) Verfahren und mittel zur behandlung von krebs
GB0313772D0 (en) Therapeutic treatment
GB2397018B (en) Combination therapy for treating disease
NO20042850L (no) Kreftbehandling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties